Comparative study using indocyanine green and patent blue dye for sentinel lymph node biopsy in patients with early-stage cervical cancer
- PMID: 38485222
- DOI: 10.1136/ijgc-2023-005206
Comparative study using indocyanine green and patent blue dye for sentinel lymph node biopsy in patients with early-stage cervical cancer
Abstract
Background: Lymphatic involvement is the most important prognostic factor in early-stage cervical cancer. Sentinel lymph node biopsy is a viable alternative to systematic lymphadenectomy and may identify metastases more precisely.
Objective: To compare two tracers (indocyanine green and patent blue) to detect sentinel nodes.
Methods: A single-center, retrospective study of women treated due to early-stage cervical cancer (International Federation of Gynecology and Obstetrics 2009 IA1 with lymphovascular invasion, IA2, and IB1). Location and tracer of all detected sentinel nodes had been documented for a prospective, multicenter trial (SENTIX trial). All sentinel nodes were sent to frozen section and final analysis through ultrastaging using a standard protocol.
Results: Overall, 103 patients were included. Bilateral detection rate for indocyanine green (93.2%) was significantly higher than for blue dye (77.7%; p=0.004). Their combined use significantly increased the bilateral detection to 99.0% (p=0.031). While 97.4% of all sentinel nodes were located below the common iliac vessels, no para-aortic nodes were labeled. Simultaneous bilateral detection with both tracers was found in 71.8% of the cases, of which the sentinel nodes were identical in 91.9%. Nine positive nodes were detected among seven patients (6.8%), all marked with indocyanine green while patent blue labeled six. Frozen section failed to detect one of three macrometastases and three of four micrometastases (sensitivity 43%; negative prediction value 96%).
Conclusion: Anatomical distribution and topographic localization of the sentinel nodes obtained with these tracers were not different. Indocyanine green provided a significantly higher bilateral detection rate and had superior sensitivity to detect positive nodes compared with patent blue. Combining indocyanine green and blue dye increased the bilateral detection rate significantly.
Keywords: Cervical Cancer; Cervix Uteri; Sentinel Lymph Node; Surgical Oncology.
© IGCS and ESGO 2024. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: None declared.
Similar articles
-
Sentinel lymph node mapping with indocyanine green using SPY-PHI in open radical hysterectomy or trachelectomy.Int J Gynecol Cancer. 2024 Jan 5;34(1):28-34. doi: 10.1136/ijgc-2023-004787. Int J Gynecol Cancer. 2024. PMID: 38097350
-
Sentinel node assessment for diagnosis of groin lymph node involvement in vulval cancer.Cochrane Database Syst Rev. 2014 Jun 27;2014(6):CD010409. doi: 10.1002/14651858.CD010409.pub2. Cochrane Database Syst Rev. 2014. PMID: 24970683 Free PMC article.
-
Factors associated with bilateral sentinel lymph node mapping failure using indocyanine green in patients with apparent early-stage cervical cancer: An Italian retrospective multi-center study.Eur J Surg Oncol. 2025 Jul;51(7):109981. doi: 10.1016/j.ejso.2025.109981. Epub 2025 Mar 20. Eur J Surg Oncol. 2025. PMID: 40199160
-
Assessment of sentinel Lymph node mapping with different volumes of Indocyanine green in early-stage ENdometrial cancer: the ALIEN study.Int J Gynecol Cancer. 2024 Jun 3;34(6):824-829. doi: 10.1136/ijgc-2023-005100. Int J Gynecol Cancer. 2024. PMID: 38336372
-
Sentinel Lymph Node Biopsy in the Management of Vulvar Carcinoma: An Evidence-Based Insight.Int J Gynecol Cancer. 2017 Oct;27(8):1769-1773. doi: 10.1097/IGC.0000000000001075. Int J Gynecol Cancer. 2017. PMID: 28763369 Review.
Cited by
-
The clinical value of carbon nanoparticles in sentinel lymph node biopsy for early vulvar cancer.Heliyon. 2024 Aug 17;10(16):e36307. doi: 10.1016/j.heliyon.2024.e36307. eCollection 2024 Aug 30. Heliyon. 2024. PMID: 39247310 Free PMC article.